The U.S. swine industry have been bearing the financial impact of Porcine Reproductive and Respiratory Syndrome (PRRS) for decades. Absent of a safe and efficacious vaccine to combat PRRS virus’s genetic heterogeneity, it remains a costly disease on pig farms across the country. We have developed virus-like-particle (VLP) based vaccines that incorporate 4 PRRSV epitopes in the hepatitis B core antigen (HBcAg) backbone. Administration of the vaccines in female BALB/C mice resulted in extremely significant PRRSV epitope specific antibody response. One vaccine candidate GP3-4 was able to mount a significant viral neutralizing response against both parental PRRSV strain VR2385 and heterologous PRRSV strain NADC20, showing a promising potential for cross-protection against PRRSV.

几十年来，美国养猪业一直对猪繁殖与呼吸综合症（PRRS）产生财务影响。由于缺乏安全有效的疫苗来对抗PRRS病毒的遗传异质性，在全国各地的养猪场中，它仍然是一种代价高昂的疾病。我们已经开发了基于病毒样颗粒（VLP）的疫苗，该疫苗在乙型肝炎核心抗原（HBcAg）骨架中包含4个PRRSV表位。在雌性BALB / C小鼠中施用疫苗会导致极为显着的PRRSV表位特异性抗体反应。一种候选疫苗GP3-4能够针对亲代PRRSV株VR2385和异源PRRSV株NADC20发出显着的病毒中和反应，显示出对PRRSV的交叉保护潜力。